|
GB202020083D0
|
|
Medical use
|
|
WO2021048159A1
|
|
Assay
|
|
WO2021048081A1
|
|
Immunotherapeutic compositions
|
|
WO2021038508A1
|
|
Jet mixing lipid nanoparticle manufacturing process
|
|
GB202013262D0
|
|
Vaccine Composition
|
|
GB202012727D0
|
|
Modified host cells and uses thereof
|
|
WO2021028303A1
|
|
Mutated pglb oligosaccharyltransferase enzymes
|
|
WO2021023692A1
|
|
Process for preparing a composition comprising a protein d polypeptide
|
|
WO2021023691A1
|
|
Immunogenic composition
|
|
WO2021014385A1
|
|
Modified human cytomegalovirus proteins
|
|
WO2021013798A1
|
|
Therapeutic viral vaccine
|
|
WO2020250130A1
|
|
Mucosal vaccine formulations
|
|
WO2020245207A1
|
|
Saponin purification
|
|
WO2020229964A1
|
|
Conjugate production
|
|
GB202005769D0
|
|
Immunogenic Composition
|
|
WO2020212461A1
|
|
Antigen binding proteins and assays
|
|
WO2020187903A1
|
|
Thermostable quick-disolving thin film
|
|
WO2020182635A1
|
|
Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines
|
|
WO2020178359A1
|
|
Hepatitis b immunisation regimen and compositions
|
|
WO2020178720A1
|
|
Nutraceutical compositions
|
